Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.63 |
| ▸ | KDM1A | O60341 | 10/20 | 0.62 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.56 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764569 | 1.00 | GRIN1 (0.63) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| SCHEMBL16155821 | 0.88 | KDM1A (0.63) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| SCHEMBL15764565 | 0.88 | KDM1A (0.63) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| SCHEMBL16288707 | 0.88 | TLR2 (0.58) | GRIN1GRIN2AKDM1AKDM1BTLR2 | |
| SCHEMBL17531099 | 0.87 | KDM1A (0.62) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| SCHEMBL15764508 | 0.86 | KDM1A (0.67) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| Hydrochloric Acid SCHEMBL17133718 | 0.85 | KDM1A (0.66) | GRIN1GRIN2AKDM1AKDM1BMAOA | |
| SCHEMBL7411072 | 0.84 | CTSB (0.57) | GRIN1GRIN2ACTSB | |
| SCHEMBL27544597 | 0.84 | CTSB (0.57) | GRIN1GRIN2ACTSB | |
| SCHEMBL15764509 | 0.84 | KDM1A (0.69) | GRIN1GRIN2AKDM1AKDM1BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2927212-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | Kyoto University (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | GRIN1 319/4885GRIN2A 686/4885KDM1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.